XAUUSD — Short at Supply Rejection [Quantum Algo]

Gold bounced off the 4,155 session low and rallied back up into an intraday supply pocket near 4,176 — the same area that capped the earlier swings around 4,179–4,180. Price pushed into the zone and stalled, firing the Sell. This is a scalp short off supply: fade the recovery into resistance, target the recent demand shelf where buyers last stepped in.

Why this setup works — three confluences:

1. Supply rejection at intraday resistance. The 4,176–4,180 band has repeatedly capped price through the session. The recovery ran straight back into it and stalled — the reaction printed on the tap, giving a tight, defined ceiling to lean risk against.
2. Recovery into resistance, not breakout. The move off 4,155 is a corrective bounce back to the top of the intraday range, not a trend break. Selling into the boundary keeps risk small and gives clean room back down through the range.
3. Demand target below. The 4,164 shelf is where price based before the last push and sits as the logical draw on a rotation lower. Defined risk above supply, clean structure to book into.

Trade management:

• Entry: 4,176 (rejection off supply)
• SL: 4,180 (above the zone)
• TP1: 4,169 — take 50% off, move stop to breakeven
• TP2: 4,164 — 100% exit at the demand shelf
• R:R: ~3:1 to full target

Invalidation:
An M5 close back above 4,180. That reclaims the supply band that's held all session — buyers break the ceiling, thesis dead, just out.

The lesson:
On the lower timeframes, the levels that held all day are the ones worth trading against. When a session builds a clear resistance band and price keeps getting rejected there, the disciplined scalp is to fade the retest — not to guess a breakout. Tight stop above the ceiling, clean target at the shelf below, and let the range pay you while it holds.

Signal fired. We took it. Update coming.

Disclaimer: Not financial advice. This idea is shared for educational purposes only. Trading leveraged instruments carries substantial risk. Past performance is not indicative of future results. Always do your own research and manage your own risk.